No Data
Absci Partners With Owkin to Develop Immuno-oncology Treatment Candidates
Express News | Absci and Owkin Synergize Leading Techbio Platforms to Advance Generative AI Drug Discovery
Absci and Owkin Synergize Leading TechBio Platforms to Advance Generative AI Drug Discovery
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Absci Is Maintained at Overweight by Keybanc
Express News | Keybanc Maintains Overweight on Absci, Lowers Price Target to $5